(Q38097866)

28 August 2017

title

JNK inhibitors as anti-inflammatory and neuroprotective agents (English)

1 reference

28 August 2017

Piotr P Graczyk

1

1 reference

28 August 2017

publication date

1 April 2013

1 reference

Future Medicinal Chemistry

28 August 2017

published in

1 reference

28 August 2017

volume

5

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

539-551

1 reference

Specific activities of individual c-Jun N-terminal kinases in the brain

28 August 2017

cites work

1 reference

The role of JNK proteins in metabolism

21 January 2018

1 reference

Novel roles for JNK1 in metabolism

21 January 2018

1 reference

cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance

21 January 2018

1 reference

Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination.

21 January 2018

1 reference

Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation.

21 January 2018

1 reference

Activation of JNK signaling mediates amyloid-ß-dependent cell death

21 January 2018

1 reference

Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy

21 January 2018

1 reference

Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease.

21 January 2018

1 reference

Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases

21 January 2018

1 reference

JNK: A Stress-Activated Protein Kinase Therapeutic Strategies and Involvement in Alzheimer’s and Various Neurodegenerative Abnormalities

21 January 2018

1 reference

MAPKs and their relevance to arthritis and inflammation

21 January 2018

1 reference

The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development

21 January 2018

1 reference

Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.

21 January 2018

1 reference

JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain

21 January 2018

1 reference

MAPK signaling in inflammation-associated cancer development

21 January 2018

1 reference

Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation

21 January 2018

1 reference

Role of JNK in mammary gland development and breast cancer

21 January 2018

1 reference

Molecular mechanisms of neonatal brain injury

21 January 2018

1 reference

The c-jun kinase/stress-activated pathway: regulation, function and role in human disease

21 January 2018

1 reference

Specific pathophysiological functions of JNK isoforms in the brain

21 January 2018

1 reference

A critical role of neural-specific JNK3 for ischemic apoptosis

21 January 2018

1 reference

Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene

21 January 2018

1 reference

JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease

21 January 2018

1 reference

Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain

21 January 2018

1 reference

Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis

21 January 2018

1 reference

JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis

21 January 2018

1 reference

A central role for JNK in obesity and insulin resistance

21 January 2018

1 reference

Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes

21 January 2018

1 reference

Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes

21 January 2018

1 reference

c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction

21 January 2018

1 reference

c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress

21 January 2018

1 reference

JNK1 but not JNK2 promotes the development of steatohepatitis in mice

21 January 2018

1 reference

c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice

21 January 2018

1 reference

Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway

21 January 2018

1 reference

Differential requirement for c-Jun N-terminal kinase 1 in lung inflammation and host defense

21 January 2018

1 reference

Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model

21 January 2018

1 reference

JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

21 January 2018

1 reference

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation

21 January 2018

1 reference

JNK3 maintains expression of the insulin receptor substrate 2 (IRS2) in insulin-secreting cells: functional consequences for insulin signaling

21 January 2018

1 reference

The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.

21 January 2018

1 reference

The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7

21 January 2018

1 reference

Small molecule JNK (c-Jun N-terminal kinase) inhibitors.

21 January 2018

1 reference

Inhibitors of c-Jun N-terminal kinases: JuNK no more?

21 January 2018

1 reference

c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.

21 January 2018

1 reference

Targeting JNK3 for the treatment of neurodegenerative disorders

21 January 2018

1 reference

Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death

21 January 2018

1 reference

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

21 January 2018

1 reference

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

21 January 2018

1 reference

JNK inhibition and inflammation after cerebral ischemia

21 January 2018

1 reference

Excitotoxicity-induced endocytosis mediates neuroprotection by TAT-peptide-linked JNK inhibitor

21 January 2018

1 reference

c-Jun N-terminal kinase signaling pathway in excitotoxic cell death following kainic acid-induced status epilepticus

21 January 2018

1 reference

The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria.

21 January 2018

1 reference

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

21 January 2018

1 reference

Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice

21 January 2018

1 reference

The JNK inhibitor XG-102 protects against TNBS-induced colitis

21 January 2018

1 reference

Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration

21 January 2018

1 reference

A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia

21 January 2018

1 reference

The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways

21 January 2018

1 reference

Delayed inhibition of c-Jun N-terminal kinase worsens outcomes after focal cerebral ischemia

21 January 2018

1 reference

Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay

21 January 2018

1 reference

The c-Jun N-terminal kinase inhibitor SP600125 is neuroprotective in amygdala kindled rats

21 January 2018

1 reference

Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease.

21 January 2018

1 reference

Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease

21 January 2018

1 reference

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

Blockage by SP600125 of Fcepsilon receptor-induced degranulation and cytokine gene expression in mast cells is mediated through inhibition of phosphatidylinositol 3-kinase signalling pathway

21 January 2018

1 reference

The JNK pathway regulates the In vivo deletion of immature CD4(+)CD8(+) thymocytes

21 January 2018

1 reference

Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2.

21 January 2018

1 reference

c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation

21 January 2018

1 reference

Axonal degeneration as a therapeutic target in the CNS.

21 January 2018

1 reference

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

21 January 2018

1 reference

Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene

21 January 2018

1 reference

Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers.

21 January 2018

1 reference

Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases

21 January 2018

1 reference

Biozzi mice: of mice and human neurological diseases

21 January 2018

1 reference

Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement.

21 January 2018

1 reference

Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor

21 January 2018

1 reference

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

21 January 2018

1 reference

Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors

21 January 2018

1 reference

Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase

21 January 2018

1 reference

Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK

21 January 2018

1 reference

Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1.

21 January 2018

1 reference

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration

21 January 2018

1 reference

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

21 January 2018

1 reference

Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury

21 January 2018

1 reference

Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor

21 January 2018

1 reference

Synthesis, Biological Evaluation, X-ray Structure, and Pharmacokinetics of Aminopyrimidine c-jun-N-terminal Kinase (JNK) Inhibitors

21 January 2018

1 reference

Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors

21 January 2018

1 reference

Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors

21 January 2018

1 reference

Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors

21 January 2018

1 reference

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

21 January 2018

1 reference

Tofacitinib for the treatment of rheumatoid arthritis

21 January 2018

1 reference

21 January 2018

Janus kinase inhibitors

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.13.34

1 reference

28 August 2017

1 reference